Agilent Posts 32 Percent Jump in Q2 Revenues, Strong LC and Mass Spec Sales | GenomeWeb

Agilent Technologies reported a 32 percent rise in its fiscal second-quarter revenues year over year, with its Life Sciences segment seeing a 39 percent jump driven, in part, by more than 20 percent growth in sales of its mass spectrometry and liquid chromatography platforms.

Life Science revenues were $464 million, up from $334 million in Q2 of last year. Overall, the company posted revenues of $1.68 billion for the quarter, up from $1.27 billion a year ago and beating analyst estimates of $1.6 billion.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Genome Research this week: vervet genome, tandem repeats affect gene expression in great apes, and more.

Wired's Sarah Zhang writes that the fight over who developed the CRISPR/Cas9 genome editing tool first underscores the history of parallel discoveries in science.

Recent research indicates that the benefit of having a number of scientists all living and working in a certain area is eroding.

Tomas Lindahl, Paul Modrich, and Aziz Sancar share this year's Nobel Prize in Chemistry for their studies of DNA repair mechanisms.